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Amajor goal of cell therapy for vascular diseases is to
promote revascularization through the injection of
endothelial stem/progenitor cells. The gene regula-
tory mechanisms that underlie endothelial pro-
genitor-mediated vascular repair, however, remain
elusive. Here, we identify the transcription factor
TAL1/SCL as a key mediator of the vascular repair
function of primary human endothelial colony-form-
ing cells (ECFCs). Genome-wide analyses in ECFCs
demonstrate that TAL1 activates a transcriptional
program that promotes cell adhesion and migration.
At the mechanistic level, we show that TAL1 upregu-
lates the expression of migratory and adhesion
genes through recruitment of the histone acetyl-
transferase p300. Based on these findings, we estab-
lish a strategy that enhances the revascularization
efficiency of ECFCs after ischemia through ex vivo
priming with the histone deacetylase inhibitor TSA.
Thus, small molecule epigenetics drugs are effective
tools for modifying the epigenome of stem/progeni-
tor cells prior to transplantation as a means to
enhance their therapeutic potential.
INTRODUCTION
Ischemic diseases occur when blood flow is interrupted or
decreased and critical organs are deprived of oxygen. It has
been well established that one of the most important factors in
saving an organ after acute vascular injuries (such as acute
limb ischemia, myocardial infarction, and stroke) is how quickly
blood flow can be restored (Creager et al., 2012; Callum and
Bradbury, 2000). Therefore, a major goal of cell therapy for
vascular diseases is to increase the kinetics of blood flow recov-
ery. Endothelial progenitors represent one of the most promising644 Cell Stem Cell 14, 644–657, May 1, 2014 ª2014 Elsevier Inc.cell-based strategies for increasing the rate of vascular repair
after ischemic tissue damage (Leeper et al., 2010). Since the
initial identification of cells with angiogenic properties in human
peripheral blood (Asahara et al., 1997), diverse populations
have been isolated under the common nomenclature ‘‘endothe-
lial progenitor cells’’ (EPCs) and analyzed for their capacity to
stimulate vascular repair following ischemic injuries (Fadini
et al., 2012; Yoder, 2012). Overall, despite some uncertainty
regarding the identity of various EPC populations, it has been
well established that several sources of EPC-like cells are able
to efficiently respond to ischemia by increasing capillary density,
blood perfusion, and organ function. Furthermore, multiple
studies have led to the view that different populations of EPCs
improve vascular regeneration through different mechanisms,
including (1) incorporation into injured endothelium followed by
differentiation to form new blood vessels (e.g., Schwarz et al.,
2012 and Ziebart et al., 2008) and/or (2) release of proangiogenic
factors in the vicinity of the injured vessels to facilitate a coordi-
nated repair process (e.g., Grunewald et al., 2006).
Endothelial colony-forming cells (ECFCs) (Ingram et al., 2004),
also referred to as blood outgrowth endothelial cells (Lin et al.,
2000), represent a homogeneous subpopulation of EPCs that
can be isolated from human cord blood and peripheral blood.
ECFCs possess unique properties that make them particularly
attractive for cell-based regenerative therapy. First, ECFCs
display robust clonal proliferative potential and express relatively
high levels of telomerase (Ingram et al., 2004; Reinisch et al.,
2009). In addition, they are able to differentiate into endothelial
capillary-like tubes in vitro (Bouvard et al., 2010; Ingram et al.,
2004; Reinisch et al., 2009) and form de novo functionally active
human blood vessels in vivo (Au et al., 2008; Melero-Martin et al.,
2007; Yoder et al., 2007). Most importantly, ECFCs have a
demonstrated capacity to enhance revascularization when in-
jected in animal models of ischemia (Bouvard et al., 2010; Saif
et al., 2010; Schwarz et al., 2012). Whereas these studies have
highlighted the potential of ECFCs for regeneration after
ischemic injuries, we know very little about the molecular mech-
anism underlying the repair properties of these human progenitor
cells that possess important clinical potential.
Figure 1. The Knockdown of TAL1 Does Not
Affect ECFCs Survival and Proliferation
(A and B) TAL1 level is decreased in ECFCs after
lentiviral delivery of anti-TAL1 shRNA relative to a
control scrambled shRNA, as measured by qRT-
PCR (A) and western blot (B).
(C) TAL1 KD does not induce necrosis or apoptosis
as measured by fluorescence-activated cell sort-
ing (FACS) after 7-AAD and annexin V staining,
respectively.
(D) TAL1 KD has no effect on the proliferation of
ECFCs as measured by FACS after EdU incorpo-
ration.
In (A), error bars represent SD of biological tripli-
cates. In (B), molecular masses are in kDa. In (C)
and (D), results have been reproduced multiple
times (n > 3) with ECFCs obtained from different
donors (n > 2). See also Figure S1.
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TAL1 Transcriptional Network in ECFCsStudies in mouse and zebrafish have established that tran-
scription factors are primary determinants of vasculogenesis
and angiogenesis during development (De Val and Black,
2009). In particular, the class II basic helix loop helix transcription
factor TAL1 (also called SCL) is a critical regulator of the endo-
thelial lineage. Indeed, TAL1 is required for specification of the
hemogenic endothelium (Lancrin et al., 2009; Patterson et al.,
2005) and for remodeling of the vasculature during development
(Dooley et al., 2005; Shivdasani et al., 1995; Visvader et al.,
1998). In addition, a recent study showed that, in the hemogenic
endothelium, TAL1 acts as a determinant of endothelial cell fate
through the inhibition of cardiomyogenesis (Van Handel et al.,
2012). Postnatally, TAL1 is expressed in immature and newly
formed blood vessels, including the tumor vasculature, whereas
it is downregulated in quiescent endothelium (Chetty et al., 1997;
Kallianpur et al., 1994). The significant contribution of TAL1 to
developmental angiogenesis suggests that TAL1 could be
important for the therapeutic function of injected ECFCs in the
regeneration of blood vessels.
Here, we show that TAL1 is essential for mediating the
vascular repair function of human ECFCs. Precisely, the role of
TAL1 is to establish the transcriptional program that drives the
migration of ECFCs by way of a mechanism that entails TAL1-
mediated recruitment of the histone acetyltransferase p300 to
specific effector genes. Finally, we show that treatment of
ECFCs ex vivo with the histone deacetylase inhibitor TSA in-
creases the expression of key genes within the TAL1 gene regu-
latory network and transplantation of these ‘‘primed’’ ECFCs
increases the kinetics of blood flow recovery in mice with
ischemic vascular injury.
RESULTS
TAL1 Is Necessary for Vascular Repair by Injected
ECFCs
It is currently unknown whether TAL1 contributes to the thera-
peutic benefits of injected ECFCs to promote revascularization.
To address this question, ECFCs were derived from humanumbilical cord blood using established protocols (Yoder et al.,
2007). Phenotypic characterization confirmed that ECFCs
display a typical, endothelial ‘‘cobblestone’’ morphology (Fig-
ure S1A available online) and express the early marker CD34
as well as a series of endothelial cell surface markers (CD31,
CD105, CD144, vascular endothelial growth factor receptor 2,
and von Willebrand factor), whereas they are devoid of the
hematopoietic marker CD45 and the monocyte/macrophage
marker CD14 (Figure S1B). To induce the knockdown (KD) of
TAL1, ECFCs were infected with lentiviruses that express anti-
TAL1 small hairpin RNA (shRNA) (or a scrambled shRNA as a
control; Palii et al., 2011a, 2011b), resulting in a significant
decrease of TAL1 levels (Figures 1A, 1B, and S2). We note that
the KD of TAL1 does not affect the survival of ECFCs as
measured by 7-amino-actinomycin D (7-AAD) and annexin V
staining (Figure 1C) or their capacity to proliferate as measured
by 5-ethynyl-20-deoxyuridine (EdU) incorporation (Figure 1D).
To determinewhether the KD of TAL1 affects the ability of ECFCs
to repair vascular injury, we used a mouse model of hindlimb
ischemia. In this experiment, ischemia was induced by ligation
of the left femoral artery, followed by ECFCs-mediated cell trans-
plantation. Consistent with previous reports (Bouvard et al.,
2010; Saif et al., 2010; Schwarz et al., 2012), injected ECFCs
engraft into the ischemic muscle and display in vivo formation
of blood vessels (Figures 2A and S1C). Furthermore, injected
ECFCs increase arteriole density in the ischemic muscle
(Figure 2B), which leads to a significantly improved blood
perfusion recovery (Figure 2C). In contrast, ECFCs expressing
reduced amounts of TAL1 do not engraft in the ischemic
muscle and fail to improve blood flow recovery and arteriole den-
sity (Figure 2). Together, these results demonstrate that TAL1 is
essential for the therapeutic revascularization function of in-
jected ECFCs.
TAL1 Is Essential for the Migration and Adhesion
Properties of ECFCs
To better understand the failure of ECFCs with TAL1 KD to pro-
mote revascularization in the ischemia animal model, we firstCell Stem Cell 14, 644–657, May 1, 2014 ª2014 Elsevier Inc. 645
Figure 2. TAL1 Is Indispensable for the Vascular Repair Capacity of ECFCs
(A) Human ECFCs participate in the formation of blood vessels in vivo in a TAL1-dependent manner. Immunostaining was performed on ischemic muscles cry-
osectionswithahuman-specificmitochondrial antibody (Ab) (hMito, green) andasmoothmuscleactinAb (SMA, red) 14daysafter injectionofPBS (nocells), ECFCs
(control shRNA), or ECFCs with a KD of TAL1 (TAL1 shRNA). Nuclei were stained with DAPI (blue). Arrows indicate human cells. The scale bar represents 50 mm.
(B) ECFCs with a KD of TAL1 fail to increase arteriole density in the ischemic muscle. Top panel, representative images of arterioles (SMA+, red) and nuclei (DAPI,
blue) at day 14 in the ischemic muscle. The scale bar represents 50 mm. Bottom panel, quantification of SMA+ vessels. FOV, field of view.
(C) ECFCs with a KD of TAL1 fail to improve blood perfusion recovery in a mouse model of hindlimb ischemia. Relative blood flow (ischemic/nonischemic
hindlimb) was measured by laser Doppler perfusion imaging immediately after induction of hindlimb ischemia (ligation) and at the indicated time points after
intramuscular injection of PBS (no cells), unmodified ECFCs (no shRNA), or ECFCs infected with a lentivirus expressing either an anti-TAL1 shRNA (TAL1 shRNA)
or a scrambled shRNA (control shRNA).
In (B) and (C), results are expressed as the mean ± SEM (six mice per group, two independent cord blood donors for each group). *p < 0.05; **p < 0.01.
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TAL1 Transcriptional Network in ECFCsexamined the capacity of these cells to form a vascular network
upon differentiation on extracellular Matrigel and collagen
matrices. We found that ECFCs with reduced levels of TAL1
are unable to form complete, fully connected capillary-like struc-
tures (Figure 3A), demonstrating that TAL1 is essential for in vitro
angiogenesis of ECFCs.
To identify the step(s) of vessel morphogenesis that are regu-
lated by TAL1, we sought to examine the consequences of TAL1
KD on ECFC adhesion, migration, and chemotaxis. First, we
tested the adhesion property of ECFCs and found that adhesion
is severely compromised by the KD of TAL1 (Figure 3D). Then, a
radius cell migration assay was used to measure the kinetics of
ECFC migration toward a central ‘‘cell-free’’ zone. This experi-
ment revealed a major defect in the migration of TAL1 KD cells
with virtually no cells invading the central area, in contrast to con-
trol ECFCs, which completely fill the central gap within 30 hr
(Figure 3B). As migration toward the chemokine stromal-cell-646 Cell Stem Cell 14, 644–657, May 1, 2014 ª2014 Elsevier Inc.derived factor 1 (SDF-1) is essential for the recruitment of endo-
thelial progenitors to sites of ischemic injury (Ceradini et al.,
2004), we also tested the migration of ECFCs by chemotaxis
toward SDF-1 in a modified Boyden chamber assay. Upon
TAL1 KD, we observed a marked reduction in the migration of
ECFCs toward SDF-1 (Figure 3C). SDF-1 regulates cell motility
through binding to the CXC chemokine receptor 4 (CXCR4)
that is present at the surface of endothelial cells. Therefore, we
measured the levels of CXCR4 in TAL1 KD ECFCs. We found
that ECFCs with a KD of TAL1 express reduced levels of
CXCR4 both ex vivo prior to transplantation (Figure 3E) and
in vivo after transplantation in the ischemic muscle (Figure 3F).
These results show that the SDF-1/CXCR4 axis is intact in
ECFCs and is altered upon TAL1 KD.
In summary, results from the phenotypic analyses upon TAL1
KD establish TAL1 as a major mediator of ECFCs-mediated
blood vessel morphogenesis.
Figure 3. TAL1 Is Indispensable for Adhesion, Migration, and Chemotaxis of ECFCs
(A) TAL1 KD leads to a profound defect in capillary-like structure formation after ECFCs plating onMatrigel and collagen. Left panel, quantification of the average
length of capillary-like structures and the number of junctions, respectively, by automatic counting with the AngioQuant software. Right panel, representative
images (bright field). The scale bar represents 50 mm for the left-most row and 20 mm for the middle and right rows.
(B) TAL1 KD inhibits ECFCs migration as measured by gap closure assay. Left panel, number of ECFCs that have invaded a defined ‘‘cell-free’’ zone (inside
of white circle on the right panel) at the indicated time points (n = 3). Right panel, cells at the 30 hr time point that were fixed and stained. The scale bar
represents 20 mm.
(legend continued on next page)
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TAL1 Transcriptional Network in ECFCsGenome-wide Mapping of TAL1 Target Genes in ECFCs
To gain further insight into the molecular mechanism through
which TAL1 promotes adhesion and migration, we set out to
identify TAL1 target genes in ECFCs. Genome-wide occupancy
of TAL1 in ECFCswas investigated by chromatin immunoprecip-
itation coupled to massively parallel DNA sequencing (ChIP-
seq). As a negative control, ChIP-seq was performed using
normal immunoglobulin G (IgG). This experiment led to the iden-
tification of 1,679 TAL1-binding sites genome-wide (p < 105;
Figure 4). An analysis based on the rate of conversion of back-
ground to foreground signal (Fong et al., 2012; Palii et al.,
2011b) indicates that sequencing depth was sufficient for
genome-wide coverage (data not shown). Validating the quality
of ChIP-seq data, TAL1 binding was confirmed by independent
ChIP-quantitative PCR (qPCR) on all tested sites (Figures 5A
and S3A). Importantly, a decrease in ChIP signal is observed
upon TAL1 KD, which validates the specificity of TAL1 ChIP (Fig-
ures 5A and S3A).
To identify DNA sequences that are statistically overrepre-
sented under the peaks of TAL1 binding, we used a de novo
motif search algorithm (Fong et al., 2012; Palii et al., 2011b).
Enriched DNA motifs include E-boxes (i.e., TAL1-binding site),
as well as binding sites for GATA, ETS, and FOX families of
transcription factors (Figure 4A; see Figure S4A for a complete
list of motifs). Furthermore, a search for preferred distances
between DNA sequences led to the identification of composite
motifs that are overrepresented under the peaks of TAL1 bind-
ing, including an E-box_GATA motif and an ETS_E-box motif
(Figures 4B and S4B).
Assigning ChIP-seq peaks to gene regulatory elements (GREs)
revealed that TAL1 occupiesmostly intronic (32%) and intergenic
(36%) regions of the genome (Figure 4C). Importantly, some of
these distal sites have been validated previously in transgenic
mouse embryos as being functional endothelial enhancers
such as the intronic enhancer of the Gata2 gene (Khandekar
et al., 2007). In addition to distal GREs, TAL1 binds to proximal
promoters (Figure 4C) with the region around the transcription
start site (TSS) containing the highest density of TAL1 peaks (Fig-
ure 4D). Examples of genes with proximal promoter binding of
TAL1 include both known (CDH5; Deleuze et al., 2007) and, to
our knowledge, novel (EPHB4; Figure 4E) endothelial targets.
To gain insight into the overall function of TAL1 target genes in
ECFCs, we performed a global search for overrepresented func-
tional categories using the Genomic Regions Enrichment of
Annotation Tool (GREAT) v.2.02 (McLean et al., 2010). This anal-
ysis revealed that TAL1 target genes are highly enriched within
functional categories related to the formation of blood vessels
such as ‘‘blood vessel development’’ (p = 1.37 3 1021), ‘‘blood
vessel morphogenesis’’ (p = 5.64 3 1020), and ‘‘angiogenesis’’
(p = 6.983 1018; Figure 4F; Table S1). Furthermore, TAL1 target(C) TAL1 KD decreases ECFCs migration by chemotaxis toward SDF-1 as meas
(D) TAL1 KD decreases ECFCs adhesion on plate (n = 3).
(E) Reduction of CXCR4 levels in TAL1 KD ECFCs prior to transplantation. qRT-PC
reduced (TAL1 shRNA) levels of TAL1 using primers specific for human CXCR4 (
(F) Reduction of human CXCR4 levels in murine ischemic muscles transplanted w
muscle frommice previously injected with PBS (no cells), ECFCs (control shRNA),
relative to rodent GAPDH ± SEM (n = 3 mice per group).
In (A)–(E), error bars represent SD of biological triplicates. See also Figure S2.
648 Cell Stem Cell 14, 644–657, May 1, 2014 ª2014 Elsevier Inc.genes are enriched within regulatory pathways that are critical to
the vascular system including platelet-derived-growth-factor-
and vascular endothelial growth factor (VEGF)-signaling path-
ways (Figure 4G; Table S1). For example, TAL1 binds to an active
endothelial enhancer upstream of the gene coding for the proan-
giogenic growth factor VEGFA (Figure S6A). Finally, enriched
categories from the Mouse Genome Informatics (MGI) expres-
sion database indicate that TAL1 target genes are expressed
in the arterial system, dorsal aorta, and decidua (Figure 4H; Table
S1). Overall, this global analysis indicates that, in ECFCs, TAL1
binds to genes that are involved in the formation of blood ves-
sels, a result that is highly consistent with our finding that TAL1
is essential for postnatal revascularization by injected ECFCs
(Figure 2).
To identify, among TAL1 target genes, those that are function-
ally dependent on TAL1 for their expression, we profiled gene-
expression changes occurring upon TAL1 KD in ECFCs (using
Affymetrix microarray on three independent ECFCs clones
generated from three distinct cord blood donors; see Table S1)
and intersected the list of statistically significant changing genes
with the list of TAL1 targets (Table S1). Validating this experi-
ment, CDH5, a previously known TAL1-activated gene (Deleuze
et al., 2007), which codes for the adherens junction molecule
vascular endothelial-cadherin was identified and confirmed by
ChIP-qPCR and quantitative RT-PCR (qRT-PCR) (Figure 5A). In
addition, our analysis revealed multiple TAL1-activated genes
that are involved in promoting endothelial cell migration and
adhesion. For example, TAL1 activates the gene coding for the
ephrin-B2 ligand (EFNB2; Table S1; Figure 5A), a transmem-
brane tyrosine kinase that mediates cell-cell contact through
its interaction with EphB receptors (mostly EphB4). Ephrin-B2
plays a critical role in angiogenesis and vasculogenesis (Salvucci
and Tosato, 2012). Interestingly, the EPHB4 gene, which codes
for ephrin-B2 receptor, is also targeted by TAL1 (Figure 4E),
but its expression does not change upon TAL1 KD in ECFCs
(data not shown), highlighting the importance of performing
gene-expression profiling in addition to ChIP-seq. In addition
to CDH5 and EFNB2, multiple other genes that are known to
play important roles in cell migration and adhesion were identi-
fied as TAL1 targets (Figure S3B; Table S1). Thus, TAL1 activates
multiple ‘‘effector’’ genes that directly impact the function of
endothelial progenitors by promoting cell migration and adhe-
sion. Besides effector genes, our results show that TAL1 also
activates genes encoding transcription factors that are them-
selves essential for endothelial cell function. Notably, we identi-
fied the genes coding for SOX7 (Costa et al., 2012) and HOXA9
(Bruhl et al., 2004) as being directly bound to and activated by
TAL1 (Figure 5A).
Taken together, these data suggest that TAL1 promotes
migration and adhesion of ECFCs both directly through theured in a modified Boyden chamber migration assay (n = 3).
R was performed on RNA isolated from ECFCs with normal (control shRNA) or
hCXCR4). qRT-PCR values are expressed relative to human GAPDH (n = 3).
ith TAL1 KD ECFCs. qRT-PCR was performed on RNA isolated from ischemic
or TAL1 KD ECFCs (TAL1 shRNA). qRT-PCR values for hCXCR4 are expressed
Figure 4. ChIP-Seq Analysis of TAL1 Genomic Binding in ECFCs
(A) Top four DNA motifs overrepresented under the peaks of TAL1 binding as identified by de novo motif discovery.
(B) Composite motifs overrepresented under the peaks of TAL1 binding.
(C) Genomic distribution of TAL1-binding sites.
(legend continued on next page)
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TAL1 Transcriptional Network in ECFCsactivation of critical effector genes (e.g., EFNB2 and CDH5) and
indirectly through the activation of transcription factors that
in turn modulate endothelial cell function (e.g., SOX7 and
HOXA9). Thus, our results provide a molecular mechanism to
explain the phenotypic effects (decrease in migration and adhe-
sion) observed upon TAL1 KD in ECFCs.
TAL1 Recruits the Histone Acetyltransferase p300 to
Activate Gene Expression
Next, we sought to determine the mechanism through which
TAL1 activates gene expression in ECFCs. Because TAL1 inter-
acts with the histone acetyltransferase (HAT) p300 in erythroid
cells (Huang et al., 1999), we hypothesized that TAL1 could acti-
vate transcription through the recruitment of this coactivator.
Consistent with this, ChIP experiments demonstrate that p300
is bound to TAL1-activated genes CDH5, EFNB2, SOX7, and
HOXA9 in ECFCs (Figure 5B). Furthermore, the KD of p300 de-
creases the expression of these genes (Figure 5C) and leads to
important defects in the capacity of ECFCs to migrate and to
form a vascular network (Figures S5A and S5B), similar to the
phenotypic effects observed upon TAL1 KD. Importantly, p300
binding is lost on TAL1 target genes upon TAL1 KD (Figure 5B),
which confirms the dependence on TAL1 for p300 recruitment.
Finally, the loss of p300 binding upon TAL1 KD is accompanied
by a decrease in histone H3 acetylation (Figure 5D) and gene
transcription (Figure 5A). Taken together, these results demon-
strate that, in ECFCs, TAL1 activates gene expression through
the recruitment of p300 that leads to increased histone acetyla-
tion (Figure 6G, left panel).
The Histone Deacetylase Inhibitor TSA Enhances the
Migratory Capacity of ECFCs through a TAL1-
Dependent Mechanism
Genome-wide studies have shown that active genes regulated
by HATs are also targeted by histone deacetylases (HDACs)
that serve to temper histone acetylation levels (Wang et al.,
2009). This suggests that HDAC inhibitors could increase
gene transcription by displacing the balance toward a higher
level of histone acetylation. To test this possibility, we first
examined whether ex vivo treatment of ECFCs with the
HDAC inhibitor TSA increases the expression of TAL1-depen-
dent genes. We found that incubation of ECFCs with TSA
leads to a 2- to 3-fold increase in histone H3 acetylation level
(Figure 6A) and in the expression level (Figure 6B) of TAL1-
dependent genes. Furthermore, TSA treatment leads to an
increased binding of the bromodomain-containing histone ace-
tyltransferase p300 (Zeng and Zhou, 2002) at TAL1 target
genes (Figure 6D). These results are consistent with a model
in which TSA treatment increases gene transcription by dis-
placing the balance toward a higher level of histone acetylation
(Figure 6G).(D) Frequency of TAL1 peak location relative to the closest TSS.
(E) TAL1 binds to the EPHB4 gene proximal promoter. TAL1 and negative control
University of California, Santa Cruz genome browser. The EPHB4 gene is depict
(F) Gene Ontology (GO) biological process analysis for TAL1 target genes (top fiv
(G) PANTHER pathway analysis for TAL1 target genes (top three pathways).
(H) Expression of TAL1 target genes in the MGI database (top four categories).
For a full list of motifs (A and B), see Figure S4. For a full list of enriched categor
650 Cell Stem Cell 14, 644–657, May 1, 2014 ª2014 Elsevier Inc.Next, we wanted to determine whether TSA treatment could
also affect the TAL1 protein. First, we examined TAL1 subcellular
localization and found no change in TAL1 nuclear staining upon
TSA treatment (Figure S5C). Second, we explored whether TSA
treatment could modify the acetylation status of TAL1. Consis-
tent with a previous study (Huang et al., 2000), we detected
strong acetylation of TAL1 in the murine erythroleukemia (MEL)
cell line (Figure S5D, right panel). In contrast, we could not detect
acetylated TAL1 in ECFCs under the same conditions (Fig-
ure S5D, left panel). Most importantly, TAL1 acetylation status
is not changed upon TSA treatment of either MEL cells or ECFCs
(Figure S5D). Finally, we examinedwhether TSA treatment would
alter TAL1 genomic binding in ECFCs. We repeated TAL1 ChIP-
seq experiments in TSA-treated versus nontreated ECFCs and
compared TAL1 genome-wide binding between the two condi-
tions. We found a very high correlation for TAL1 binding in
TSA-treated versus nontreated ECFCs with a Pearson correla-
tion coefficient of 0.96 (Figure 6E, left panel). To assess the sig-
nificance of this result, we performed multiple comparisons of
published TAL1 ChIP-seq data sets. This analysis indicated
that TAL1 binding in TSA-treated and nontreated ECFCs dis-
plays a level of similarity as good as or better than TAL1 binding
between ChIP-seq replicates (Figure S5E). Furthermore, the
ChIP-seq enrichment profiles show no change in TAL1 binding
on a large portion of chromosome 6 (Figure 6E, right) and on
the VEGFA locus (Figure S6A). Therefore, TAL1 genomic binding
is not altered upon TSA treatment of ECFCs. Altogether, these
results support the model depicted in Figure 6G where TSA
treatment of ECFCs actsmostly through increasing histone acet-
ylation and gene expression rather than modifying TAL1 binding
to the genome.
As TAL1 activates genes involved in migration, we reasoned
that treatment of ECFCs with TSA could improve the migratory
capacity of ECFCs. Consistent with this hypothesis, we found
that TSA treatment, whereas not affecting the morphology of
ECFCs (Figure 7A), leads to a striking increase in the migration
kinetics of these cells (Figure 6F). Importantly, this effect is
dependent on TAL1 as the migration of TSA-treated ECFCs is
abolished upon TAL1 KD (Figure 6F). Taken together, these re-
sults demonstrate that TSA treatment increases the migratory
capacity of ECFCs through a TAL1-mediated mechanism.
TSA Treatment Enhances ECFCs Revascularization
Efficiency
In the clinical setting, it has been shown that one of the most
important factors in saving an organ after acute ischemia is
how quickly blood flow can be restored (Creager et al., 2012;
Callum and Bradbury, 2000). Thus, our finding that TSA in-
creases the kinetics of ECFC migration (Figure 6F) suggests
that this treatment might have an important clinical impact by
increasing the speed at which blood flow can be restored after(IgG) ChIP-seq density plots were generated from raw data and loaded into the
ed at the bottom.
e categories).
ies (F–H), see Table S1. See also Figures S3 and S4.
Figure 5. TAL1 Activates Gene Expression through Recruitment of the Acetyltransferase p300 and Increase in Histone H3 Acetylation
(A) Validation of TAL1-activated genes in ECFCs.
(B) p300 is recruited to TAL1 target genes in a TAL1-dependent manner.
(C) The KD of p300 leads to a decrease in the expression of TAL1 target genes. siRNA, small interfering RNA.
(D) The KD of TAL1 leads to a decrease in histone H3 acetylation on its target genes.
(legend continued on next page)
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TAL1 Transcriptional Network in ECFCsischemic injury. To test this hypothesis, ECFCs were pretreated
with TSA ex vivo prior to transplantation into ischemic mouse
muscle. We found that TSA treatment leads to a dramatic in-
crease in the rate of blood flow recovery because mice injected
with TSA-treated ECFCs attain 90% of maximal blood flow
recovery as early as 4 days after cell therapy compared to
10 days for mice injected with non-TSA-treated cells (Figures
7B and 7C). Therefore, ex vivo treatment with TSA significantly
improves the kinetics of ECFC-mediated vascular repair in vivo.
Importantly, the effect of TSA on ECFCs is mediated at least in
part through TAL1 target genes as decreases in migration and
blood flow recovery are also observed upon knockdown of the
TAL1 target gene CDH5 in TSA-treated cells (Figures S6D–S6H).
To obtain additional insight into the mechanism through which
ex vivo treatment with TSA improves the in vivo function of trans-
planted ECFCs, we measured arteriole density in the ischemic
muscle. We found that, 4 days after injection, arteriole density
is increased by 60% in mice transplanted with TSA-treated
ECFCs (Figure 7D), which is highly consistent with the increased
kinetics of blood flow recovery (Figures 7B and 7C). Further-
more, we observed less necrosis in the ischemic muscle of
mice injected with TSA-treated ECFCs compared to mice in-
jected with unmodified ECFCs (data not shown). Taken together,
these results confirm that in vivo revascularization is more effi-
cient with TSA-treated ECFCs. Interestingly, we also detect a
strong increase in the expression of human CXCR4 in vivo in
the ischemic muscle of mice transplanted with TSA-treated
ECFCs (Figure 7F), suggesting that TSA treatment increases
the SDF-1/CXCR4 axis that is essential for migration of ECFCs.
However, we do not observe a higher percentage of vessels con-
taining human ECFCs in mice injected with TSA-treated ECFCs,
even though both TSA-treated and nontreated cells engraft in the
ischemic muscle after 4 days (Figure 7E). Finally, we detect a
strong increase in the level of human VEGFA (a TAL1-target
gene; Figures S6A–S6C) in vivo in the ischemic muscle of mice
transplanted with TSA-treated ECFCs (Figure 7G), suggesting
that TSA can also improve the paracrine function of ECFCs.
Taken together, these results suggest that ex vivo treatment
with TSA improves the revascularization potential of ECFCs
both by promoting migration via increased CXCR4 expression
and through paracrine effects via increased expression of
VEGFA that can act both on ECFCs and on resident murine
endothelial cells.
DISCUSSION
Revascularization by injected ECFCs is a promising strategy to
enhance vascular repair in ischemic diseases (Bouvard et al.,
2010; Moubarik et al., 2011; Saif et al., 2010; Schwarz et al.,
2012). Despite significant advances in our understanding of
ECFCs, the gene-regulatory mechanisms that control the func-
tion of these therapeutically important cells remain elusive.
Focusing on the transcription factor TAL1, we present here
an in-depth characterization of human primary ECFCs in theFor (A), (B), and (D), ChIP-qPCR and qRT-PCR were performed in the presence o
Ab or IgG as a negative control. For (C), qRT-PCR was performed in the presence
values are expressed as a fraction of input with error bars corresponding to SD. q
bars corresponding to SD. For a full list of TAL1 target genes, see Table S1.
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regenerative therapy. First, we demonstrate that TAL1 is neces-
sary for the postnatal revascularization function of human ECFCs
in vivo. Interestingly, we found that TAL1 is required for the
migration and adhesion of ECFCs, but not for their proliferation.
Mechanistically, resolution of the genome-wide TAL1 regulatory
network demonstrates that this effect is mediated by the ability
of TAL1 to directly activate multiple adhesion and migration
effector genes through epigenetic mechanisms that entail
recruitment of the acetyltransferase p300 and subsequent his-
tone H3 acetylation. Finally, using the HDAC inhibitor TSA, we
are able to further increase histone acetylation levels, leading
to increased expression of TAL1 target genes, which in turn
significantly improves the vascular repair function of ECFCs.
Thus, our study provides proof of principle that HDAC inhibitors
can be used to ameliorate the therapeutic function of ECFCs.
Studies at theGene Level AreEffective inOptimizing the
Design of New and Improved Therapies Using Stem/
Progenitor Cells
Characterization of the TAL1 transcriptional network in ECFCs
allowed us to identify a major role for this factor in the activation
of genes that are essential mediators of endothelial cell function.
Furthermore, we showed that TAL1 activates these genes
through recruitment of the HAT p300. This mechanistic insight
served as the basis for examining the HDAC inhibitor TSA as a
potential epigenetic drug to augment the vascular repair function
of ECFCs in vivo. Thus, themechanistic study of TAL1was a pre-
requisite for designing a strategy to improve the therapeutic
function of ECFCs. In addition, molecular studies allowed us to
measure the effect of TSA directly on the acetylation and expres-
sion status of TAL1-dependent genes, which was essential to
precisely adjust the dose of TSA and avoid potentially adverse
effects such as inhibition of endothelial differentiation that is
observed when TSA is used at higher concentrations (Ro¨ssig
et al., 2005; C.G.P., S.F., and M.B., unpublished data). This
illustrates how mechanistic insights into gene-regulatory mech-
anisms may be exploited to develop improved therapeutic stra-
tegies using stem/progenitor cells.
Improving ECFC Therapeutic Potential through
Epigenetic Drugs
Here, we have shown that stimulating ECFCs by pretreatment
with the HDAC inhibitor TSA enhances their therapeutic poten-
tial. Specifically, ex vivo treatment of ECFCs with TSA markedly
increases the rate of blood flow recovery, a highly desirable goal
in the context of acute ischemic diseases where the rapidity of
restoring oxygen supply to hypoxic tissues is critical for patient
recovery (Creager et al., 2012). To our knowledge, this is the first
study demonstrating that ex vivo priming with an epigenetic drug
prior to transplantation can dramatically improve the revascular-
ization efficiency of ECFCs. Furthermore, this approach has
many advantages. First, administering the drug to the cells, as
opposed to the patient, limits potentially adverse secondaryf normal (control shRNA) or reduced (TAL1 shRNA) levels of TAL1 using a TAL1
of normal (control siRNA) or reduced (p300 siRNA) levels of p300. ChIP-qPCR
RT-PCR values are expressed relative to the internal control GAPDH with error
Figure 6. TSA Treatment Increases the Expression of TAL1 Target Genes and Augments the Migratory Capacity of ECFCs
(A and B) TSA treatment increases histone H3 acetylation (A) and expression (B) of TAL1 target genes.
(C) TSA treatment does not change TAL1 binding to its target genes.
(D) TSA treatment stabilizes p300 binding to TAL1 target genes.
(E) TSA treatment does not alter TAL1 binding genome wide. Left panel, correlation plot of TAL1 genomic binding in TSA-treated (x axis) versus untreated (y axis)
ECFCs as measured by ChIP-seq. The Pearson’s linear correlation coefficient (R value) is indicated (also see Figure S5E). Right panel, representative example of
TAL1 binding to a 6 Mb region on chromosome 6. IgG ChIP-seq served as a negative control.
(F) Pretreatment with TSA increases themigration kinetics of ECFCs in a TAL1-dependentmanner. Migration of ECFCs containing normal (Ctrl shRNA) or reduced
(TAL1 shRNA) levels of TAL1 and pretreated with TSA (+TSA) or not (TSA) was measured by counting the number of cells that have invaded a central cell-free
zone at the indicated time points (n = 3). Error bars correspond to SD.
(legend continued on next page)
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accessibility of ex-vivo-cultured ECFCs facilitates the optimiza-
tion of drug dosage to achieve maximal therapeutic benefit.
Finally, in contrast to gene therapy approaches that work
through modifying the genome to ameliorate stem cell func-
tion, changes in gene expression triggered by epigenetic drugs
are transient and as such less likely to have long-term, poten-
tially harmful consequences to the patient. This is particularly
relevant for endothelial progenitors as uncontrolled vasculariza-
tion can facilitate tumor growth and metastasis (Liu et al., 2012).
Thus, ex vivo treatment with HDAC inhibitors may provide an
efficient approach to augment the therapeutic potential of hu-
man ECFCs.
The TAL1 Gene-Regulatory Network in ECFCs
Resolution of the TAL1 transcriptional network by ChIP-seq and
gene-expression profiling suggests that TAL1 is part of a larger
network of transcription factors that regulate ECFCs. First,
TAL1 directly binds to and activates the genes coding for tran-
scription factors SOX7 and HOXA9, both of which are essential
regulators of endothelial cells (Bruhl et al., 2004; Costa et al.,
2012). Furthermore, analysis of the DNA sequence under TAL1
peaks identified several motifs that are recognized by transcrip-
tion factors of the GATA, ETS, and FOX families, suggesting that
TAL1 could cooperate with these factors to regulate gene
expression. Interestingly, comparing the DNA sequences over-
represented under TAL1 peaks in ECFCs versus cells of the
hematopoietic lineage, we note that somemotifs are reminiscent
of TAL1 binding in hematopoiesis (i.e., E-box_GATA [Fujiwara
et al., 2009; Palii et al., 2011b; Soler et al., 2010; Wilson et al.,
2010] and ETS_E-box [Palii et al., 2011b]), whereas others
appear specific to ECFCs such as a FOX motif (Figure 4A).
This suggests that TAL1 cooperates with distinct factors in
ECFCs versus hematopoietic cells. Taken together, these data
emphasize that TAL1 is part of a larger transcriptional regulatory
network that comprises many other factors with which it inter-
acts to regulate gene expression in ECFCs.
Whereas we have shown that TAL1 mediates the vascular
repair function of ECFCs, future studies toward resolving the
complete transcriptional regulatory network in ECFCs will be
required to identify additional transcription factors that promote
cellular functions that are complementary to migration such as
proliferation, differentiation, and angiogenic signaling. This will
facilitate the identification of additional epigenetic drugs to be
used in combination with HDAC inhibitors to further enhance
the therapeutic value of ECFCs.
EXPERIMENTAL PROCEDURES
Cell Culture
Human ECFCs were derived from umbilical cord blood (n = 12) obtained after
full-term deliveries and cultured essentially as described (Yoder et al., 2007).
Informed consent was obtained prior to cord blood collection, and all proce-(G) Model of TSA-mediated increase in the migratory function of ECFCs through
genes through the recruitment of p300 and subsequent histone acetylation. Rig
toward increasing TAL1-mediated histone acetylation and transcription of migra
For (A), (C), and (D), ChIP-qPCR was performed in ECFCs pretreated with TSA (+T
to the no TSA control with error bars corresponding to SD. For (B), qRT-PCRwas p
are expressed as the level of transcript relative to the no TSA control with error b
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(2006460-01H). All experiments were performed with at least three biologically
independent ECFC colonies originating from three distinct cord blood donors.
See Supplemental Experimental Procedures for details.
TAL1 Knockdown
The KD of TAL1 was performed by lentivirus-mediated shRNA delivery as
previously described (Palii et al., 2011a, 2011b). ECFCs were infected twice
at 24 hr interval. The western blot and qRT-PCR showing TAL1 KD were per-
formed 48 hr after the first lentiviral infection (time 0). All phenotypic assays
were started at time 0. See Supplemental Experimental Procedures for
details.
Treatment of ECFCs with the HDAC Inhibitor TSA
Paired samples of 70% confluent ECFCs in complete endothelial cell growth
medium-2 medium were treated with 100 ng/ml final TSA (cat no. 19-138;
Upstate Millipore) or a vehicle control for 24 hr. Cells were washed with PBS
prior to harvesting.
Mouse Model of Hindlimb Ischemia
Procedures were performed on 8- or 9-week-old athymic nude CD1 female
mice as previously described (Kuraitis et al., 2011) with the approval of the
University of Ottawa Animal Care Committee and in accordance with the
National Institute of Health Guide for the Care and Use of Laboratory Animals.
Unilateral left hindlimb ischemia in mice was induced by ligating the proximal
end of the femoral artery using 4-0 silk surgical suture as described in Lim-
bourg et al. (2009). The overlying skin was then closed by a 5-0 proline suture.
Cell therapy was administered immediately after skin closure. Specifically,
0.5 million ECFCs that were either nontreated or treated as indicated (infection
with lentiviruses or TSA treatment) were resuspended in 50 ml PBS and deliv-
ered by two equivolumetric injections into the adductor muscle downstream of
the ligation site using an insulin syringe. The PBS control group received 50 ml
of PBS only.
Laser Doppler Analysis
Blood perfusion analysis was performed preoperatively, immediately after sur-
gery, and at the indicated days postoperation by laser Doppler perfusion
imaging (moorLDI2; Moor Instruments). Results are expressed as the ratio of
ischemic to nonischemic hindlimb perfusion.
Statistical Analysis
Statistical analyses were performed using Student t test unless otherwise indi-
cated. Bonferroni correction was applied for multiple comparison analyses.
Data represent results from at least three independent experiments. Data
represent mean ± SEM. p < 0.05 was considered statistically significant.
Gene Expression Profiling on Affymetrix Microarray
Total RNA from three independent ECFC colonies (derived from three distinct
cord blood donors), each with or without a TAL1 KD, was analyzed by hybrid-
ization to the Affymetrix Human Gene 1.0 ST gene expression microarray. See
Supplemental Experimental Procedures for details.
ChIP
Enrichment of acetylated histone H3 was measured using a native ChIP proto-
col (Brand et al., 2008). Binding of transcription factors was measured using a
crosslink ChIP protocol (Palii et al., 2011b). For qPCR, DNAwas quantifiedwith
SYBROgreen using a standard curve generated with genomic DNA and was
normalized by dividing the amount of the corresponding target in the input
fraction. For details on high-throughput DNA-sequencing experiments and
analyses see Supplemental Experimental Procedures.a TAL1-mediated mechanism. Left: TAL1 activates transcription of migration
ht: Inhibition of HDAC activity through TSA treatment displaces the balance
tion genes.
SA) or not (TSA). ChIP-qPCR values are expressed as the enrichment relative
erformed in ECFCs pretreatedwith TSA (+TSA) or not (TSA). qRT-PCR values
ars corresponding to SD. See also Figure S5.
Figure 7. Ex Vivo Treatment with TSA Increases the Efficiency of ECFC-Mediated Revascularization after Ischemia
(A) Representative photomicrographs of ECFCs monolayers with or without TSA treatment (original magnification 1003). The scale bar represents 10 mm.
(B and C) Ex vivo treatment with TSA increases the kinetics of blood flow recovery by injected ECFCs in a mousemodel of hindlimb ischemia. Relative blood flow
wasmeasured by laser Doppler perfusion imaging immediately after induction of hindlimb ischemia (Lig.) and at the indicated time points after injection of PBS (no
cells), untreated ECFCs (ECFCs), or ECFCs pretreated with TSA (ECFCs+TSA). For (B), representative laser Doppler images are shown. Isch., ischemic leg;
NI, nonischemic leg. For (C), mean values with error bars representing SEM (n = 3 mice for no cells; n = 3 mice for ECFCs; n = 4mice for ECFCs+TSA). **p = 0.008
for ECFCs+TSA relative to ECFCs-injected mice (indicated on graph). p < 0.05 at all time points for ECFCs+TSA relative to no cells control and at all time points
(except day 2) for ECFCs relative to no cells control.
(legend continued on next page)
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See Supplemental Experimental Procedures.
qPCR and qRT-PCR Primers
See Supplemental Experimental Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus accession numbers for the microarray data,
ChIP-seq data for TAL1 binding in ECFCs, and ChIP-seq data for TAL1 binding
in TSA-treated versus untreated ECFCs reported in this paper are GSE44444,
GSE44442, and GSE53423, respectively. All data sets are also saved under
the common accession number GSE44546.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
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